Childhood Medulloepithelioma Completed Phase 1 Trials for Vorinostat (DB02546)

IndicationStatusPhase
DBCOND0030159 (Childhood Medulloepithelioma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00994500Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaTreatment
NCT01076530Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord TumorsTreatment